PHILADELPHIA, Pennsylvania — A combination of dextromethorphan and quinidine (Nuedexta, Avanir Pharmaceuticals) significantly reduced symptoms of pseudobulbar affect (PBA) among patients with dementia ...
Axsome Therapeutics received FDA acceptance and priority review designation for its supplemental new drug application for AXS-05, a treatment for agitation associated with Alzheimer’s disease. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results